WCRX Warner Chilcott Limited featured news, full reports, and detailed charts
Warner Chilcott Limited (WCRX) Wrap Up:
We are a leading specialty pharmaceutical company currently focused on the women’s healthcare and dermatology segments of the U.S. pharmaceutical market. We are a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of our products. We have established strong franchises in women’s healthcare and dermatology through our marketing techniques and specialty sales forces, which now comprise approximately 500 representatives. We believe that our proven product development capabilities, coupled with our ability to execute acquisitions and in-licensing transactions and develop partnerships, such as our relationship with LEO Pharma A/S (“LEO Pharma”), will enable us to sustain and grow these franchises. Our primary manufacturing facility is located in Fajardo, Puerto Rico. Our franchises are comprised of complementary portfolios of established branded and development-stage products. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f02%2f29%2f0001193125-08-042124.html#FIS_BUSINESS"www.warnerchilcott.com
1,115 Employees
Founded in 1968
Warner Chilcott plc (WCRX:NASDAQ)
LAST $22.98 USD
CHANGE TODAY -0.17 -0.73%
VOLUME 9.7M
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Warner Chilcott plc (WCRX)
|
OPEN
$22.45
|
PREVIOUS CLOSE
$23.15
|
|
|
DAY HIGH
$22.98
|
DAY LOW
$22.30
|
|
|
52 WEEK HIGH
10/12/09 - $24.45
|
52 WEEK LOW
03/6/09 - $9.24
|
|
|
MARKET CAP
5.8B
|
AVERAGE VOLUME 3 mo
1.4M
|
|
|
DILUTED EPS TTM
$1.62
|
SHARES OUTSTANDING
251.5M
|
|
|
WCRX Does Not Pay Dividends
|
P/E TTM
14.2x
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Is M&A on a Slow Upswing?
08/31/2009 9:14 PM ET
Deals such as Disney-Marvel and Baker Hughes-BJ Services suggest that merger-and-acquisition activity is gradually picking up. But don't expect a quick recovery
Stocks Finish Mixed
08/24/2009 4:25 PM ET
An early rally attempt fizzled Monday as investors turned cautious after the market's recent gains
related news
*Warner Chilcott prices secondary stock offering
AP Digital - 11/20/2009 9:14 AM ET
WCRX Top Compensated Officers
Mr. Roger M. Boissonneault
Chief Executive Officer, President and Direct...
Age: 60
Total Annual Compensation: $960.0K
Mr. Paul Herendeen
Chief Financial Officer, Principal Accounting...
Age: 53
Total Annual Compensation: $418.7K
Mr. W. Carl Reichel
President of Pharmaceuticals
Age: 50
Total Annual Compensation: $450.9K
Ms. Izumi Hara Esq.
Senior Vice President, General Counsel and Co...
Age: 49
Total Annual Compensation: $313.8K
Mr. Anthony Bruno
Executive Vice President of Corporate Develop...
Age: 53
Total Annual Compensation: $432.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Warner Chilcott plc (WCRX)
Warner Chilcott plc Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/9/2009
Warner Chilcott plc reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported income before income taxes of $449,829,000, adjusted EBITDA of $158,909,000, net income of $424,245,000 or $1.69 per diluted share on total revenue of $252,795,000, net cash provided by operating activities of $111,054,000 and capital expenditure of $13,760,000 compared to income before income taxes of $46,505,000, adjusted EBITDA of $134,213,000, net income of $40,089,000 or $0.16 per diluted share on total revenue of $231,939,000, net cash provided by operating activities of $90,040,000 and capital expenditure of $134,213,000 for the same period a year ago. Adjusted cash net income was $103,229,000 compared to $96,517,000 for the same period in 2008. For the nine months ended September 30, 2009, the company reported income before income taxes of $568,114,000, adjusted EBITDA of $451,479,000, net income of $523,604,000 or $2.09 per diluted share on total revenue of $749,600,000, net cash provided by operating activities of $340,928,000 and capital expenditure of $32,793,000 compared to income before income taxes of $130,013,000, adjusted EBITDA of $382,134,000, net income of $107,315,000 or $0.43 per diluted share on total revenue of $695,638,000, net cash provided by operating activities of $210,174,000 and capital expenditure of $13,328,000 for the same period a year ago. Adjusted cash net income was $310,144,000 compared to $263,658,000 for the same period in 2008.
Dong-A Pharmtech Announces Start of Phase III Trials for Udenafil
11/4/2009
Dong-A PharmTech Co. Ltd. announced that Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo. The trials will be conducted in 80 sites in the U.S. and will enroll approximately 1,120 subjects with ED. If approved, udenafil is expected to participate in a growing prescription ED market by offering a long acting and safe product that will compete with Viagra (Pfizer), Cialis (Lilly) and Levitra (Bayer/GSK).
Warner Chilcott plc, Q3 2009 Earnings Call, Nov-09-2009
11/2/2009
Warner Chilcott plc, Q3 2009 Earnings Call, Nov-09 2009
WCRX Competitors
| Company | Last | Change |
| Allergan Inc | $58.62 USD | -0.03 |
| Elan Corporation | €4.36 EUR | +0.039 |
| Medicis Pharmaceutical Corp | $23.49 USD | +0.03 |
| Valeant Pharmaceuticals International | $33.28 USD | -0.38 |
| Watson Pharmaceuticals Inc | $35.15 USD | -0.38 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | WCRX | Industry Range |
| Price/Earnings | 14.1x |
|
| Price/Sales | 5.8x |
|
| Price/Book | 3.0x |
|
| Price/Cash Flow | 9.1x |
|
| TEV/Sales | 4.7x |
|
|
WCRX |
||
|
WCRX transactions
| Type Date |
Target |
|
Merger/Acquisition
August 24, 2009 |
Procter & Gamble Co., Global Pharmaceuticals Business |
More Recent News About Warner Chilcott Limited
More news for WCRX
Indian Pharmaceutical Stock Picks From Citi Investment Research: The Sub Continent Goes Global WIth Drug Manufacturing Partnerships
67 WALL STREET, New York - November 5, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); Ne...Click here to read the whole Article (external link)
Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2009
ARDEE, Ireland, Nov. 9 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX - News) today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX. The Company reported net income of $424.2 million ($1.69 per diluted share) in the quarter ended September 30, 2009, compared with net income of $40.1 million ($0.16 per diluted share) in the prior year quarter. The quarter ended September 30, 2009 included a gain of $380.1 million ($1.51 per diluted share), net of tax, related to the termination, for $1.0 billion in cash from LEO Pharma A/S ("LEO"), of Warner Chilcott's exclusive product licensing rights in the United States to TACLONEX, TACLONEX SCALP, DOVONEX and all other products in LEO's development pipeline, as well as the sale to LEO of related assets (the "LEO Transaction"). Cash net income ("CNI") as reported in the quarter ended September 30, 2009 was $483.3 million. Excluding the gain of $380.1 million, adjusted CNI was $103.2 million ($0.41 per diluted share).References in this release to "cash net income" or "CNI" mean the Company's net income adjusted for the after-tax effects of two non-cash items: amortization (including impairments, if any) of intangible assets and amortization (including w...Click here to read the whole Article (external link)
Leo Pharma payment lifts Warner Chilcott 3Q profit
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
WARNER CHILCOTT PLC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fina
Item 7.01 Regulation FD Disclosure On September 23, 2009, the Company entered into a definitive asset purchase agreement (the "LEO Transaction Agreement") with LEO Pharma A/S ("LEO") pursuant to which LEO paid the Company $1.0 billion in cash in order to terminate the Company's exclusive license to distribute LEO's DOVONEX and TACLONEX products (including all products in LEO's development pipeline) in the United States and to acquire certain assets related to the Company's distribution of DOVONEX and TACLONEX products in the United States. The transaction (the "LEO Transaction") was approved by the respective boards of directors of the Company and LEO, and closed simultaneously with the execution of the LEO Transaction Agreement. The Company intends to provide certain information to investors and reflect the impact of the consummation of the LEO Transaction on the Company, and is therefore including such information in this Current Report on Form 8-K pursuant to Regulation FD. Information set forth below (including the pro forma information filed as Exhibit 99.2) is furnished and shall not be deemed to be "filed" under the Exchange Act or incorporated by reference into any filing under the Securities Act or the Exchange Act. The following tables present certain non-GAAP financial measures on a pro forma basis giving effect to the LEO Transaction, and reconciliations to the most directly comparable GAAP financial measure. The information set forth below (including the pro forma information filed as Exhibit 99.2) does not take into account the Company's acquisition of the global prescription pharmaceutical business of The Procter & Gamble Company (the "PGP Acquisition"), except with respect to certain expenses incurred prior to the closing of the PGP Acquisition. Reconciliations to GAAP Net Income Cash Net Income To supplement its unaudited Pro Forma Condensed Consolidated financial statements presen...Click here to read the whole Article (external link)
Warner Chilcott Announces Secondary Equity Offering
ARDEE, Ireland, Nov. 13 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX - News) today announced a 20,000,000 share secondary offering of its ordinary shares by certain selling shareholders. The selling shareholders include funds affiliated with Bain Capital Partners, DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners, L.P., certain other institutional investors and members of the Company's senior management. The offering is being conducted as a public offering pursuant to an effective shelf registration statement under the Securities Act of 1933. The Company will not receive any proceeds from the sale of the shares but will pay the expenses of the offering. The offering is being made through an underwriting syndicate, led by Goldman, Sachs & Co., Morgan Stanley, Credit Suisse and J.P. Morgan. The co-managers of the offering are BofA Merrill Lynch, Barclays Capital, Citi, Deutsche Bank Securities and UBS Investment Bank.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be a sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The offering is being made by means of a prospectus supplement and the accompanying prospectus only. Copies of the prospectus supplement and accompanying prospectus can be obtained by contacting Goldman, Sachs &a...Click here to read the whole Article (external link)
WARNER CHILCOTT PLC Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits
Show all filings for WARNER CHILCOTT PLC | Request a Trial to NEW EDGAR Online Pro Form 8-K/A for WARNER CHILCOTT PLC 13-Nov-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informatio...Click here to read the whole Article (external link)
Funds to sell 20M Warner Chilcott shares
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
WARNER CHILCOTT PLC Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue252,795 250,816 245,989 242,487 Cost of Revenue44,366 46,962 48,750 53,193 Gross Profit208,429 203,854 197,239 189,294 Operating ExpensesResearch Development11,627 11,945 23,872 15,233 Selling General and Administrative59,115 53,022 46,766 44,401 Non Recurring - - - 163,316 Others56,993 56,992 56,993 59,083 Total Operating Expenses - - - 282,033 Operating Income or Loss80,694 81,895 69,608 (92,739)Income from Continuing OperationsTotal Other Income/Expenses Net393,127 14 65 181 Earnings Before Interest And Taxes473,821 81,909 69,673 (92,558)Interest Expense23,992 15,215 18,082 21,066 Income Before Tax449,829 66,694 51,591 (113,624)Income Tax Expense25,584 10,671 8,255 2,048 Minority Interest - - - - Net Income From Continuing Ops424,245 56,023 43,336 (115,672)Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes ...Click here to read the whole Article (external link)
Would you like to leave a comment about Warner Chilcott Limited WCRX
Find out what social network information about Warner Chilcott Limited are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Warner Chilcott Limited there is more great information available at Realpennies.com